利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

88 条记录 (耗时 0.04 秒)

    CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY
    3.
    发明申请
    CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY 有权

    公开(公告)号：US20220363732A1

    公开(公告)日：2022-11-17

    申请号：US17621931

    申请日：2020-06-30

    申请人： MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ -GEMEINSCHAFT ,  CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN

    发明人： Antonio PEZZUTTO ,  Thomas BLANKENSTEIN ,  Nese CAKMAK-GÖRÜR ,  Elmehdi BELBARAKA

    IPC分类号： C07K14/725 ,  C12N15/113

    摘要： The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides nucleic acids encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1 or 33, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners.

    NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS
    9.
    发明申请
    NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS 审中-公开

    公开(公告)号：US20200155484A1

    公开(公告)日：2020-05-21

    申请号：US16775156

    申请日：2020-01-28

    申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

    发明人： ULRIKE STEIN ,  WOLFGANG WALTHER ,  ULRIKE SACK ,  PETER M. SCHLAG

    IPC分类号： A61K31/167 ,  A61K31/4035 ,  A61K45/06

    摘要： A method for inhibiting, reducing and/or reducing the risk of cancer metastasis in a subject, including identifying a subject as in need of inhibiting, reducing and/or reducing the risk of cancer metastasis, by identifying the subject as having a cancer with an elevated or up-regulated level of S100A4 transcription compared to a level in non-oncogenic cells, and administering to the subject a therapeutically effective amount of niclosamide or a niclosamide derivate, thereby inhibiting or reducing S100A4 transcription, so as to inhibit, reduce and/or reduce the risk of cancer metastasis, wherein 15 to 400 mg niclosamide or niclosamide derivate is administered per kg body weight of the subject (mg/kg), 1 or 2 times daily.